Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
April 8, 2024
April 8, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
Teva announces recruitment completion of phase 3 clinical study of mdc-TJK
January 9, 2024
January 9, 2024
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
May 22, 2023
MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
May 4, 2023
May 4, 2023
MedinCell: SAIVE Study data to be presented at ECCMID 2023 Euronext: MEDCL
April 17, 2023
April 17, 2023
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
January 24, 2023
January 24, 2023
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
January 5, 2023
January 5, 2023
Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive
